Reuters: Regulatory News: EU follows U.S. lead in studying diabetes drugs risks

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

EU follows U.S. lead in studying diabetes drugs risks Mar 26th 2013, 15:19 LONDON, March 26 | Tue Mar 26, 2013 11:19am EDT LONDON, March 26 (Reuters) - The European Medicines Agency said on Tuesday it was investigating the possibility that two widely used classes of diabetes drugs might cause inflammation of the pancreas and pre-cancerous changes. The decision to study so-called GLP-1 therapies and DPP-4 drugs follows similar action earlier this month by the U.S. Food and Drug Administration. Drugs affected include Novo Nordisk's Victoza, Merck & Co's Januvia, and Onglyza from Bristol-Myers Squibb and AstraZeneca.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions